Announcement PDF Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity Antisense Therapeutics Limited (ASX: ANP) ABN 41 095 060 745 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Charmaine Gittleson Date of last notice 22 August 2023 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Indirect Nature of indirect interest (including registered holder) Director related entity Date of change 29 November 2023 Note: Provide details of the circumstances giving rise to the relevant interest. No. of securities held prior to change Direct Indirect Total Class Number acquired Number disposed + See chapter 19 for defined terms. Shares 733,333 733,333 Options 6,667 6,667 Unlisted Options (TBC) Direct Indirect Total Shares - Options 3,000,000 3,000,000 Direct Indirect Total Shares - Options - 01/01/2011 Appendix 3Y Page 1 Appendix 3Y Change of Director’s Interest Notice Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation Non-cash, per resolution 6 approved by shareholders at the Annual General Meeting of the Company held 15 November 2023. No. of securities held after change Direct Indirect Total Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Shares 733,333 733,333 Options 3,006,667 3,006,667 Issue of options per resolution 6 approved by Antisense Therapeutics Limited shareholders at the Annual General Meeting held 15 November 2023 Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to which N/A interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired N/A Interest disposed N/A Value/Consideration N/A Interest after change N/A Note: If consideration is non-cash, provide details and an estimated valuation Part 3 – +Closed period Were the interests in the securities or contracts detailed No above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the N/A trade to proceed during this period? If prior written clearance was provided, on what date was N/A this provided? The CFO Solution + See chapter 19 for defined terms.Appendix 3Y Page 201/01/2011 Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity: Antisense Therapeutics Limited (ASX: ANP) ABN: 41 095 060 745 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director James Garner Date of last notice 21 November 2023 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Direct Nature of indirect interest (including registered holder) N/A Date of change 29 November 2023 Note: Provide details of the circumstances giving rise to the relevant interest. No. of securities held prior to change Direct Indirect Total Class Number acquired Number disposed + See chapter 19 for defined terms. Shares 1,000,000 1,000,000 Options - Unlisted Options (TBC) Direct Indirect Total Shares - Options 6,690,000 6,690,000 Direct Indirect Total Shares - Options - 01/01/2011 Appendix 3Y Page 1 Appendix 3Y Change of Director’s Interest Notice Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation No. of securities held after change Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Non-cash, per resolution 4 approved by shareholders at the Annual General Meeting of the Company held 15 November 2023. Shares Options Direct 1,000,000 6,690,000 Indirect Total 1,000,000 6,690,000 Issue of options per resolution 4 approved by Antisense Therapeutics Limited shareholders at the Annual General Meeting held 15 November 2023 Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to which N/A interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired N/A Interest disposed N/A Value/Consideration N/A Interest after change N/A Note: If consideration is non-cash, provide details and an estimated valuation Part 3 – +Closed period Were the interests in the securities or contracts detailed No above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the N/A trade to proceed during this period? If prior written clearance was provided, on what date was N/A this provided? The CFO Solution + See chapter 19 for defined terms.Appendix 3Y Page 201/01/2011